Menu

Javascript is not activated in your browser. This website needs javascript activated to work properly.
You are here

New results for galiellalactone and its effect on prostate cancer

Researchers within MAD for Cancer recently published new results for the promising STAT3 inhibitor galiellalactone and its effect on prostate cancer
STAT3
STAT-3 structure (Credits: Wikimedia Commons)

This study shows that the STAT3 inhibitor galiellalactone reduces tumor growth and metastatic spread in an animal model of prostate cancer. The article “The STAT3 Inhibitor Galiellalactone Effectively Reduces Tumor Growth and Metastatic Spread in an Orthotopic Xenograft Mouse Model of Prostate Cancer” is published in the journal European Urology

Read more

Read the article

 

 

 

 

 

Latest articles

18/09/2017
Lunds Fernströmpris till forskning om cancercellers samspel med omgivningen
Lunds Fernströmpris till forskning om cancercellers samspel med omgivningen
29/08/2017
Improved gene analysis of kidney cancer defines kidney cancer subtypes
Improved gene analysis of kidney cancer defines kidney cancer subtypes
13/06/2016
New variants of blood cancer in children
New variants of blood cancer in children
04/05/2016
A breakthrough of professor Kristian Pietras highlighted by Cancerfonden
A breakthrough of professor Kristian Pietras highlighted by Cancerfonden
08/04/2016
CREATE Health research in "Cancerfondsrapporten 2016"
CREATE Health research in "Cancerfondsrapporten 2016"